top of page
News


As part of the continued expansion and advancement of our business operations, we relocated our headquarters to Ebisu, Shibuya-ku, Tokyo on June 1, 2026.
As part of the continued expansion and advancement of our business operations, we relocated our headquarters to Ebisu, Shibuya-ku, Tokyo on June 1, 2026.
Jun 9


On May 13, 2026, our company officially entered into a cooperation agreement with NAGAWA Pharmaceutical Co., Ltd. of Japan.
On May 13, 2026, our company officially entered into a cooperation agreement with NAGAWA Pharmaceutical Co., Ltd. of Japan. Moving forward, both parties will engage in business exchange and cooperation in Japan and overseas markets, focusing on fields related to regenerative medicine, health management, and high-end medical centers. By leveraging their respective resources and expertise, both parties will continue to strengthen collaboration and communication in these areas.
May 21


A strategic partnership with authenmole (Macau) Traditional Chinese Medicine Technology Co., Ltd.
Our Company has completed its investment in Macau Wang lei Ou International Health Technology Co., Ltd., and has established a strategic partnership with the Macau-based pharmaceutical manufacturing facility operated by authenmole (Macau) Traditional Chinese Medicine Technology Co., Ltd. Moving forward, both parties will collaborate on the introduction and promotion of high-quality Japanese pharmaceutical and healthcare products. Leveraging Macau’s unique position as a region
Apr 30


Business Partnership with Macau COLOUR Aesthetic & Beauty Group (OEM Products)
Our company have entered into a strategic partnership with Macau COLOUR Aesthetic & Beauty Group to jointly develop and manufacture OEM products based on Japanese regenerative medical technology.
Dec 10, 2025


Investment in Macau JOV Medical Center
Our company have completed our investment in Macau JOV Medical Center.Specializing in anti-aging medicine and holistic health management, the center will integrate advanced Japanese regenerative medical technologies introduced by our group to deliver high-quality anti-aging and regenerative medical services to the Guangdong–Hong Kong–Macau Greater Bay Area, contributing to the enhancement of regional healthcare standards.
Dec 5, 2025


Launch of Shanghai DingLaiMei Technology Co., Ltd. and Its Cell Processing Center (CPC)
Our company is pleased to announce the completion of our investment in Shanghai Cell Processing Center (CPC), operated by Shanghai DingLaiMei Technology Co., Ltd.
This investment brings together the advanced scientific research capabilities of ShanghaiTech University and the clinical trial resources of Renji Hospital,Shanghai Jiao Tong University School of Medicine. By integrating these strengths, we will further enhance our position in the fields of cell science and regener
Nov 28, 2025
bottom of page